Conference Track

Latest Findings in HBV Management

Source: CCO Independent Conference Coverage of the 2005 Annual Meeting of the American Association for the Study of Liver Diseases*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

GLOBE: Strong Early HBV DNA Suppression Predictive of Year 1 Response in Nucleoside-Treated HBV
ETV-022: Entecavir Superior to Lamivudine for Viral Suppression at 2 Years in HBeAg(+) Chronic Hepatitis B
High HBeAg Levels During Peginterferon Treatment Negatively Predict HBeAg Seroconversion in Chronic Hepatitis B
Tenofovir More Effective Than Adefovir at Suppressing HBV DNA in Lamivudine-Resistant Chronic Hepatitis B
L-FMAU-301: Clevudine Potent and Well Tolerated in HBeAg-Positive Chronic Hepatitis B in Phase 3 Trial
Survey Suggests Divergence of Opinions Between Expert Physicians and AASLD General Members in Treatment of Chronic Hepatitis B
Virological Response and Resistance to Adefovir Therapy in Liver Transplant Recipients
Lamivudine-Resistant HBV/HIV-Coinfected Patients Respond to Long-Term Adefovir/Lamivudine Therapy With No Adefovir Resistance
High Prevalence of Significant Fibrosis in Patients With Immunotolerant Chronic Hepatitis B
No Entecavir Resistance After 2 Years of Treatment in Nucleoside-Naive Chronic Hepatitis B
High Rate of Resistance to Adefovir Monotherapy in Lamivudine-Resistant Cohort
Tenofovir Active in Patients With Lamivudine-Resistant HBV and Suboptimal Virologic Response to Adefovir, in Pilot Study
Better Virologic Response With Lamivudine Plus Adefovir vs Adefovir Alone for HBeAg-Positive Chronic Hepatitis B
GLOBE: Therapeutic Reponses Superior With Telbivudine vs Lamivudine in Patients With HBeAg-Positive Chronic Hepatitis B in Interim Analysis
Higher Doses of Pradefovir Produces Better Response Than Adefovir at 24 Weeks in Phase 2 Trial
Study 438: Long-Term Adefovir Associated With Continued Regression of Liver Fibrosis in HBeAg-Negative Chronic Hepatitis B
Clevudine Effective for HBeAg-Negative Chronic Hepatitis B in Phase 3 Trial
Entecavir Superior to Lamivudine in Patients With Compensated Cirrhosis
Tenofovir Effective in 6 Patients With Poor Response or Resistance to Adefovir

Expert Analysis

Latest Findings in HBV Management

Faculty:
Geoffrey M. Dusheiko, MD, FCP(SA), FRCP Robert G. Gish, MD Emmet B. Keeffe, MD, MACP
Robert P. Perrillo, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss the prevalence of HBV in specific subpopulations.
Review approaches for minimizing/avoiding the development of drug resistance during treatment of chronic hepatis B including rationale for the development of antiviral combinations.
Describe the results of recent studies of antiviral agents for the treatment of chronic hepatitis B, including adefovir dipivoxil, clevudine, entecavir, peginterferon, pradefovir, telbivudine, and tenofovir.

CME CREDIT INFORMATION

Release Date: 02/06/06

Expiration Date: 02/05/07

Physicians: maximum of 1.5 AMA PRA Category 1 Credit(s)™

Registered Nurses: 1.8 Nursing CE credits

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.